Search results for: Bone Morphogenetic Protein 13 (BMP 13), Human, recombinant
#28864147 2017/09/02 Save this To Up
Randomised controlled clinical trial of augmentation of the alveolar ridge using recombinant human bone morphogenetic protein 2 with hydroxyapatite and bovine-derived xenografts: comparison of changes in volume.The aim of this randomised controlled clinical trial was to assess the early efficacy of bone morphogenetic protein-2 with hydroxyapatite granules (BMP-2/hydroxyapatite) on augmentation of the alveolar ridge, by comparing changes in volume with those associated with the use of an inorganic bovine-derived xenograft (BDX). We studied 20 patients who were divided into two groups using a table of random numbers, and BMP-2/hydroxyapatite and BDX were applied accordingly. Computed tomographic (CT) images and panoramic radiographs were obtained immediately after operation and four months later. CT images were reconstructed in three dimensions to measure volumetric changes, and linear measurements were made on panoramic images. The mean (SD) absorption rates for BMP-2/hydroxyapatite and BDX were 13.2 (8.8)% and 13.8 (20.5)%, respectively. While the mean value did not differ significantly between the two materials, the SD was higher in the BDX group than in the BMP-2/hydroxyapatite group. No clinically important complications occurred in either group. We conclude that both BMP-2/hydroxyapatite and BDX were effective in augmenting the alveolar ridge, but BMP-2/hydroxyapatite seemed to be more useful in complicated bone defects.
2143 related Products with: Randomised controlled clinical trial of augmentation of the alveolar ridge using recombinant human bone morphogenetic protein 2 with hydroxyapatite and bovine-derived xenografts: comparison of changes in volume.Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Human Bone Morphogenetic Recombinant Human p16-INK Human normal bone and ost Human Macrophage Inflamma Human Macrophage Inflamma Human Gro g Macrophage In
#28212453 2017/02/17 Save this To Up
Bone Morphogenetic Protein-2 Hybridized with Nano-Anchored Oligonucleotides on Titanium Implants Enhances Osteogenic Differentiation In Vivo.Previous in vitro studies have shown that DNA oligonucleotides (ODN) can be successfully used as anchor strands for the binding and retarded release of biologically active recombinant human bone morphogenetic protein 2 (rhBMP-2). The aim of the present study was to test the hypothesis that rhBMP-2 bound to the surface of titanium implants through hybridization with nano-anchored ODN strands is biologically active and can enhance the induction of osteogenic markers in peri-implant bone in vivo.
2062 related Products with: Bone Morphogenetic Protein-2 Hybridized with Nano-Anchored Oligonucleotides on Titanium Implants Enhances Osteogenic Differentiation In Vivo.Human Bone Morphogenetic Polyclonal Antibody Bone Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Human Macrophage Inflamma Human Macrophage Inflamma Human Gro g Macrophage In Mouse Macrophage Inflamma
#28009223 2016/12/23 Save this To Up
Development of an Enhanced Recovery After Surgery (ERAS) approach for lumbar spinal fusion.OBJECTIVE Over the past decade, Enhancing Recovery After Surgery (ERAS) programs have been implemented throughout the world across multiple surgical disciplines. However, to date no spinal surgery equivalent has been described. In this report the authors review the development and implementation of a "fast track" surgical approach for lumbar fusion. METHODS The first 42 consecutive cases in which patients were treated with the new surgical procedure were reviewed. A combination of endoscopic decompression, expandable cage deployment, and percutaneous screw placement were performed with liposomal bupivacaine anesthesia to allow the surgery to be performed without general endotracheal anesthesia. RESULTS In all cases the surgical procedure was performed successfully without conversion to an open operation. The patients' mean age (± SD) was 66.1 ± 11.7 years, the male/female ratio was 20:22, and a total of 47 levels were treated. The mean operative time was 94.6 ± 22.4 minutes, the mean intraoperative blood loss was 66 ± 30 ml, and the mean hospital length of stay was 1.29 ± 0.9 nights. Early follow-up showed a significant improvement in the mean Oswestry Disability Index score (from 40 ± 13 to 17 ± 11, p = 0.0001). Return to the operating room was required in 2 cases due to infection and in 1 case due to cage displacement. An iterative quality improvement program demonstrated areas of improvement, including steps to minimize infection, improve postoperative analgesia, and reduce cage osteolysis. CONCLUSIONS ERAS programs for improving spinal fusion surgery are possible and necessary. This report demonstrates a first foray to apply these principles through 1) a patient-focused approach, 2) reducing the stress of the operation, and 3) an iterative improvement process.
1854 related Products with: Development of an Enhanced Recovery After Surgery (ERAS) approach for lumbar spinal fusion.MOUSE ANTI BOVINE ROTAVIR MOUSE ANTI BORRELIA BURGD succinate-CoA ligase, GDP formin-like 1 antibody So succinate-CoA ligase, ADP Primary antibody Caspase Primary antibody FLIP An Cultrex In Vitro Angiogen Analysis Tool for Custom Analysis Tool for Custom RABBIT ANTI GSK3 BETA (pS Endothelial Tube Formatio
#27726186 2016/10/11 Save this To Up
Localized bone regeneration around dental implants using recombinant bone morphogenetic protein-2 and platelet-derived growth factor-BB in the canine.To test whether or not one of two biological mediators (recombinant human bone morphogenetic protein-2 (rhBMP-2) and recombinant human platelet-derived growth factor (rhPDGF-BB)) is superior to the other and compared with control groups for bone regeneration around implants based on histomorphometrical outcome measures.
1621 related Products with: Localized bone regeneration around dental implants using recombinant bone morphogenetic protein-2 and platelet-derived growth factor-BB in the canine.Human Platelet Derived Gr Mouse Platelet Derived Gr Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Human Platelet Derived Gr Human Platelet Derived Gr Human Bone Morphogenetic Mouse Platelet Derived Gr
#27669712 2016/09/27 Save this To Up
Bone morphogenetic protein-2 provokes interleukin-18-induced human intervertebral disc degeneration.Interleukin 18 (IL-18) is a regulatory cytokine that degrades the disc matrix. Bone morphogenetic protein-2 (BMP-2) stimulates synthesis of the disc extracellular matrix. However, the combined effects of BMP-2 and IL-18 on human intervertebral disc degeneration have not previously been reported. The aim of this study was to investigate the effects of the anabolic cytokine BMP-2 and the catabolic cytokine IL-18 on human nucleus pulposus (NP) and annulus fibrosus (AF) cells and, therefore, to identify potential therapeutic and clinical benefits of recombinant human (rh)BMP-2 in intervertebral disc degeneration.
2817 related Products with: Bone morphogenetic protein-2 provokes interleukin-18-induced human intervertebral disc degeneration.Human Bone Morphogenetic Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Polyclonal Antibody Bone Rad51 Protein (Human) Rad51 Protein (Human) Rad Rad52 Protein (Human) Rad52 Protein (Human) Rad
#27385679 2016/07/07 Save this To Up
Bone Morphogenetic Protein Use and Cancer Risk Among Patients Undergoing Lumbar Arthrodesis: A Case-Cohort Study Using the SEER-Medicare Database.Recombinant bone morphogenetic proteins (BMPs) are growth factors utilized in lumbar arthrodeses. Limited data from randomized trials suggest that BMP may increase cancer risk. We sought to evaluate cancer risk and mortality following the use of BMP in lumbar arthrodesis.
1095 related Products with: Bone Morphogenetic Protein Use and Cancer Risk Among Patients Undergoing Lumbar Arthrodesis: A Case-Cohort Study Using the SEER-Medicare Database.Bone Morphogenetic Protei Polyclonal Antibody Bone Anti-BMPR1A(Bone morphoge Anti-BMPR1B(Bone morphoge Anti BMPR1B(Bone morphoge Anti-Bone Morphogenetic P Anti Bone Morphogenetic P Anti-Bone Morphogenetic P Anti Bone Morphogenetic P Anti-Bone Morphogenetic P Anti Bone Morphogenetic P Anti-Bone Morphogenetic P
#27319221 2016/06/20 Save this To Up
Delivery of rhBMP-2 Plasmid DNA Complexes via a PLLA/Collagen Electrospun Scaffold Induces Ectopic Bone Formation.The development of effective strategies for gene delivery is a critical goal in DNA-based tissue engineering. Previously, our laboratory utilized the process of electrospinning to fabricate plasmid DNA-based polymeric scaffolds. Although there lease of DNA was robust, the in vitro transfection efficiency was low. In order to optimize these results, we recently modified our approach and utilized a strategy to adsorb plasmid DNA transfection complexes onto a PLLA/Collagen I electrospun scaffold for the delivery of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2). BMP-2 was selected since it is currently clinically used to stimulate osteogenesis. Initially, we tested this approach using β-gal plasmid DNA complexes adsorbed onto PLLA/Collagen I scaffolds and obtained a transfection efficiency of 41% of that of the positive control (over 90%, DNA complexes in solution). Next, we utilized the same approach using the rhBMP-2 plasmid DNA complexes with the pre-osteoblastic. cell line, MC3T3, and detected robust (13-fold) expression of rhBMP-2 mRNA following transfection. Lastly, a mouse muscle pouch model was used to evaluate in vivo gene delivery efficacy and ectopic bone inducing capability of the scaffold adsorbed rhBMP-2 transfection complexes. Results showed that both rhBMP-2mRNA and protein were expressed and stimulated some ectopic bone formation. As such, adsorption of plasmid DNA complexes can be an effective strategy for tissue engineering in vivo, but further research is required to optimize our approach and obtain a clinically meaningful tissue response.
1514 related Products with: Delivery of rhBMP-2 Plasmid DNA Complexes via a PLLA/Collagen Electrospun Scaffold Induces Ectopic Bone Formation.ACTGene Blue Hot Start DN Recombinant Viral antige Recombinant Viral Antige DNA PKcs (Ab 2609) Antibo Viral antibodies, anti-H Cultrex 24 Well Collagen Cultrex 24 Well Collagen Apoptotic DNA Laddering K Rabbit anti DNA PKcs (Ab- Atlas HotTaq DNA Polymera ACCUZYME DNA Polymerase ACCUZYME Red DNA Polymera
#27031630 2016/04/01 Save this To Up
Bone Regeneration Using Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With and Without Collagen Membrane in Calvarial Standardized Defects: An In Vivo Microcomputed Tomographic Experiment in Rats.The aim of this in vivo microcomputed tomographic (μCT) experiment was to assess in real time the efficacy of a combination of recombinant human bone morphogenetic protein-2 (rhBMP-2) and biphasic calcium phosphate (BCP), with and without resorbable collagen membrane (CM), in regeneration of standardized calvarial defects (SCDs) in rats. A total of 30 female Wistar albino rats (n = 10/group) with a mean age and weight of 7.5 months and 275 g, respectively, were used. With the rats under general anesthesia, the calvaria were exposed using full-thickness periosteal flaps and unilateral SCDs of 4.6 mm diameter were created on the left parietal bone. Defects were left untreated (control group) or randomly filled with either BCP soaked in rhBMP-2 and then covered with CM (BMP + BCP + CM group) or BCP soaked in rhBMP-2 alone (BMP + BCP group). In vivo μCT scans were done at baseline and 2, 4, 6, and 8 weeks. Newly formed bone (NFB) and remaining BCP particles were assessed for their volumes (NFBV, BCPV, respectively) and mineral densities (NFBMD, BCPMD, respectively). In vivo μCT results showed scanty amounts of new bone at the peripheries of the defect in the control group. In the other two groups, near complete defect closure was evident at 8 weeks. The mean NFBV after 8 weeks was 4.63 ± 0.96 mm(3), 11.82 ± 1.17 mm(3), and 13.85 ± 1.89 mm(3) for the control, BMP + BCP + CM, and BMP + BCP groups, respectively. After 8 weeks, the mean NFBMD was 0.38 ± 0.03 g/mm(3), 0.24 ± 0.07 g/mm(3), and 0.35 ± 0.03 g/mm(3) for the control, BMP + BCP + CM, and BMP + BCP groups, respectively. After 8 weeks, the mean BCPV and BCPMD values for the BMP + BCP + CM and BMP + BCP groups were 2.73 ± 0.65 mm(3), 0.33 ± 0.08 g/mm(3), 2.49 ± 0.71 mm(3), and 0.28 ± 0.03 g/mm(3), respectively. The present real-time in vivo μCT experiment demonstrated that BMP + BCP, either with or without CM, was effective in promoting bone regeneration within rat SCDs and enabled new bone formation starting as early as 2 weeks.
2284 related Products with: Bone Regeneration Using Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With and Without Collagen Membrane in Calvarial Standardized Defects: An In Vivo Microcomputed Tomographic Experiment in Rats.Human normal bone and ost Alkaline Phospatase (ALP) Angiogenesis (Human) Anti Angiogenesis (Human) Anti Angiogenesis (Mouse) Anti Atherosclerosis (Human) A Atherosclerosis (Mouse) A Cytokine (Human) Antibody Cytokine (Mouse) Antibody Inflammation (Human) Anti Inflammation (Human) Anti Bone marrow tumor and adj
#26816490 2016/01/28 Save this To Up
The Prodomain-Containing BMP9 Produced from a Stable Line Effectively Regulates the Differentiation of Mesenchymal Stem Cells.BMPs play important roles in regulating stem cell proliferation and differentiation. Using adenovirus-mediated expression of the 14 types of BMPs we demonstrated that BMP9 is one of the most potent BMPs in inducing osteogenic differentiation of mesenchymal stem cells (MSCs), which was undetected in the early studies using recombinant BMP9 proteins. Endogenous BMPs are expressed as a precursor protein that contains an N-terminal signal peptide, a prodomain and a C-terminal mature peptide. Most commercially available recombinant BMP9 proteins are purified from the cells expressing the mature peptide. It is unclear how effectively these recombinant BMP9 proteins functionally recapitulate endogenous BMP9.
2806 related Products with: The Prodomain-Containing BMP9 Produced from a Stable Line Effectively Regulates the Differentiation of Mesenchymal Stem Cells.Mesenchymal Stem Cell Adi Anti C Reactive Protein A anti HSV (II) gB IgG1 (mo anti HCMV IE pp65 IgG1 (m anti HCMV gB IgG1 (monocl Epidermal Growth Factor ( Epidermal Growth Factor ( anti SLAM anti CDw150 IgG anti CD37 IgG2b (monoclon TCP-1 theta antibody Sour Mesenchymal Stem Cell Ost AP-1 Reporter – HEK293
#26775208 2016/04/19 Save this To Up
The missing effect of human recombinant Bone Morphogenetic Proteins BMP-2 and BMP-7 in surgical treatment of aseptic forearm nonunion.In this cohort study, the surgical revision concept of open compression plating and autologous bone grafting with and without additional application of BMP for treatment of aseptic ulna and/or radius shaft nonunion was evaluated. The purpose was to evaluate the clinical and radiological outcome, and to determine any difference in osseous healing, range of time between revision surgery and bone healing, and postoperative complications between the cohort groups.
1086 related Products with: The missing effect of human recombinant Bone Morphogenetic Proteins BMP-2 and BMP-7 in surgical treatment of aseptic forearm nonunion.Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Bone Morphogenetic Protei Human Bone Morphogenetic Recombinant Human BMP-2, Recombinant Human BMP-5 P Growth Differentiation Fa Growth Differentiation Fa Recombinant Human BMP-2 P
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia